Information  X 
Enter a valid email address

Accrol Group Hldgs (ACRL)

  Print   

Thursday 17 December, 2020

Accrol Group Hldgs

Notice of Half Year Results

RNS Number : 8784I
Accrol Group Holdings PLC
17 December 2020
 

17 December 2020

 

ACCROL GROUP HOLDINGS PLC
("Accrol", the "Company" or the "Group")

AIM: ACRL

 

NOTICE OF HALF YEAR RESULTS

 

Accrol Group, one of the UK's leading independent tissue converters, announces that it will release its Half Year Results for the six months to 31 October 2020 on Tuesday, 12 January 2021.

 

An analyst briefing will be held online at 9.00 am on that day. Equity analysts interested in joining the meeting should contact Belvedere Communications, see contact details below.

 

A webinar presentation for retail investors will also be held as part of the results roadshow. Details of this event will be announced in due course.

 

For further information, please contact:

 

 

 

Accrol Group Holdings plc

 

Dan Wright, Executive Chairman

Via Belvedere Communications

Gareth Jenkins, Chief Executive Officer

 

 

 

Zeus Capital Limited (Nominated Adviser & Broker) 

 

Dan Bate / Jordan Warburton

Tel: +44 (0) 161 831 1512

Dominic King / John Goold

Tel: +44 (0) 203 829 5000

 

 

Liberum Capital Limited (Joint Broker)

Tel: +44 (0) 20 3100 2222

Clayton Bush / Edward Thomas

 

 

 

Belvedere Communications Limited

 

Cat Valentine

Tel: +44 (0) 7715 769 078

Keeley Clarke

Tel: +44 (0) 7967 816 525

Llew Angus

Tel:  +44 (0) 7407 023 147

 

[email protected]

 

Overview of Accrol

 

Accrol Group Holdings plc is a leading tissue converter and supplier of toilet tissues, kitchen rolls and facial tissues to many of the UK's leading discounters and grocery retailers across the UK. Following the recent acquisition of a state-of-the-art tissue converter based in Leicester, the Group now operates from five sites, including four in Lancashire, which generate revenues totalling c.16% of the £1.7bn UK retail tissue market.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NORFQLFFBLLEFBF

a d v e r t i s e m e n t